Trial Profile
An Investigator-initiated, Randomized, Double-blind, Placebo Controlled Study of Apremilast to Demonstrate Efficacy in Subjects With Nummular Eczema
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2022
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Eczema
- Focus Therapeutic Use
- Acronyms APREMINUM
- 01 Nov 2021 This trial has been discontinued (end Date: 15 Sep 2021), according to European Clinical Trials Database record.
- 07 Oct 2021 Status changed from suspended to completed.
- 12 Apr 2021 Planned End Date changed from 1 Mar 2021 to 1 Oct 2021.